A new $3.2 million National Institutes of Health (NIH) R01 grant is helping University of Nevada, Reno School of Medicine (UNR Med) researchers delve into one of the body’s most fascinating processes ...
Stopping GLP-1 therapy may disrupt glycemic control and reduce cardiovascular benefits without clear perioperative safety ...
Patients taking a glucagon-like peptide 1 receptor agonist (GLP-1 RA) experience only a modest delay in gastric emptying of solid foods and no significant delay for liquids compared with those ...
MOVE-IT met the primary endpoint with statistically significant improvement in gastroparesis symptoms in 20 mg and 40 mg TID doses vs ...
Injected medications that treat diabetes and obesity increase the risk of a rare but serious side effect: stomach paralysis, according to new data on the real-world use of the drugs. At least three ...
The use of marijuana and new weight loss pharmaceuticals can have an impact on gastric emptying scans commonly used to evaluate patients with gastrointestinal complaints. With the increased usage of ...
Understanding how GLP-2 controls appetite could unlock new strategies for combating obesity, offering hope for more effective treatments. Study: The Possible Involvement of Glucagon-like Peptide-2 in ...
Your stomach has essentially gone on strike, and your diabetes is the reason why. Gastroparesis, which literally means stomach paralysis, is one of the most frustrating and dangerous complications of ...
Figure 1A:In the awaken and fasted state, typical MMC contractile movements were seen in the gastric body, sinus, duodenum and jejunum in beagle dogs, while the colon was dominated by intermittent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results